246 related articles for article (PubMed ID: 20358424)
1. HE4: a new potential early biomarker for the recurrence of ovarian cancer.
Anastasi E; Marchei GG; Viggiani V; Gennarini G; Frati L; Reale MG
Tumour Biol; 2010 Apr; 31(2):113-9. PubMed ID: 20358424
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
3. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
4. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.
Van Gorp T; Cadron I; Despierre E; Daemen A; Leunen K; Amant F; Timmerman D; De Moor B; Vergote I
Br J Cancer; 2011 Mar; 104(5):863-70. PubMed ID: 21304524
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
6. Bead-based ELISA for validation of ovarian cancer early detection markers.
Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
[TBL] [Abstract][Full Text] [Related]
7. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.
Chang X; Ye X; Dong L; Cheng H; Cheng Y; Zhu L; Liao Q; Zhao Y; Tian L; Fu T; Chen J; Cui H
Int J Gynecol Cancer; 2011 Jul; 21(5):852-8. PubMed ID: 21633297
[TBL] [Abstract][Full Text] [Related]
8. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
[TBL] [Abstract][Full Text] [Related]
9. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
10. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
11. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
12. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
[TBL] [Abstract][Full Text] [Related]
13. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
[TBL] [Abstract][Full Text] [Related]
15. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
16. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.
Escudero JM; Auge JM; Filella X; Torne A; Pahisa J; Molina R
Clin Chem; 2011 Nov; 57(11):1534-44. PubMed ID: 21933899
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
[TBL] [Abstract][Full Text] [Related]
19. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
20. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]